Strong network of independent researchers
BioGaia has an extensive research network and collaborates with universities and hospitals around the world, such as the Swedish University of Agricultural Sciences in Uppsala, Sweden, the Karolinska Institute in Stockholm, Sweden, Sahlgrenska University Hospital in Gothenburg, Sweden, Texas Children’s Hospital in the USA, and the University Hospitals of Bari and Turin in Italy.
BioGaia’s strains of Lactobacillus reuteri are some of the world’s most well researched probiotics, especially in young children. To date, 217 clinical studies using BioGaia’s human strains of Lactobacillus reuteri have been performed on around 18,000 individuals of all ages (January 2020). Studies have been performed on:
- Infantile colic and digestive health in children
- Antibiotic-associated diarrhoea (AAD)
- Acute diarrhoea • Gingivitis (inflammation of the gums)
- Periodontal disease • General health
- Helicobacter pylori (the gastric ulcer bacterium)
In order to ensure transparency and aim for the highest possible scientific standards, BioGaia encourages researchers to design studies and report results in a way that enables publication in well-renowned medical journals. The aim is that all studies, regardless of result, should be published. Further – more, BioGaia requires all studies to be ethically approved and registered on a public website, such as ClinicalTrials.gov.